Richard  Giroux net worth and biography

Richard Giroux Biography and Net Worth

CFO of MeiraGTx
Richard Giroux has served as our Chief Operating Officer since March 2015 and as Chief Operating Officer & Chief Financial Officer since April 2019. Mr. Giroux joined MeiraGTx from Sarissa Capital Management LP, an activist healthcare hedge fund, where he was a partner from March 2014 to March 2015. Prior to Sarissa Capital Management LP, Mr. Giroux was a founding partner and healthcare portfolio manager of Meadowvale Partners, a multi-strategy hedge fund, from January 2010 until June 2012. Prior to Meadowvale Partners, he was a partner at Sivik Global Healthcare (formerly Argus Partners), a healthcare hedge fund, from August 2001 to November 2008. Prior to that, he worked at investment banks Salomon Smith Barney and Goldman Sachs. Mr. Giroux received a B.A. in Economics from Yale University.

What is Richard Giroux's net worth?

The estimated net worth of Richard Giroux is at least $4.42 million as of January 21st, 2025. Mr. Giroux owns 849,947 shares of MeiraGTx stock worth more than $4,419,724 as of April 13th. This net worth estimate does not reflect any other investments that Mr. Giroux may own. Additionally, Mr. Giroux receives an annual salary of $2,140,000.00 as CFO at MeiraGTx. Learn More about Richard Giroux's net worth.

How old is Richard Giroux?

Mr. Giroux is currently 51 years old. There are 5 older executives and no younger executives at MeiraGTx. The oldest executive at MeiraGTx is Dr. Stuart Naylor Ph.D., Chief Development Officer, who is 61 years old. Learn More on Richard Giroux's age.

What is Richard Giroux's salary?

As the CFO of MeiraGTx Holdings plc, Mr. Giroux earns $2,140,000.00 per year. The highest earning executive at MeiraGTx is Dr. Alexandria Forbes Ph.D., CEO, President & Director, who commands a salary of $2,890,000.00 per year. Learn More on Richard Giroux's salary.

How do I contact Richard Giroux?

The corporate mailing address for Mr. Giroux and other MeiraGTx executives is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. MeiraGTx can also be reached via phone at (646) 860-7985 and via email at investors@meiragtx.com. Learn More on Richard Giroux's contact information.

Has Richard Giroux been buying or selling shares of MeiraGTx?

Richard Giroux has not been actively trading shares of MeiraGTx during the past quarter. Most recently, Richard Giroux sold 24,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a transaction totalling $150,960.00. Following the completion of the sale, the chief financial officer now directly owns 849,947 shares of the company's stock, valued at $5,346,166.63. Learn More on Richard Giroux's trading history.

Who are MeiraGTx's active insiders?

MeiraGTx's insider roster includes Alexandria Forbes (CEO), Richard Giroux (CFO), and Stuart Naylor (Insider). Learn More on MeiraGTx's active insiders.

Are insiders buying or selling shares of MeiraGTx?

During the last twelve months, MeiraGTx insiders bought shares 1 times. They purchased a total of 1,250,000 shares worth more than $5,000,000.00. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 107,339 shares worth more than $636,488.33. The most recent insider tranaction occured on April, 8th when CEO Alexandria Forbes sold 47,500 shares worth more than $253,650.00. Insiders at MeiraGTx own 8.4% of the company. Learn More about insider trades at MeiraGTx.

Information on this page was last updated on 4/8/2025.

Richard Giroux Insider Trading History at MeiraGTx

See Full Table

Richard Giroux Buying and Selling Activity at MeiraGTx

This chart shows Richard Giroux's buying and selling at MeiraGTx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k$0$100kTotal Insider BuyingTotal Insider Selling

MeiraGTx Company Overview

MeiraGTx logo
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $5.30
Low: $5.18
High: $5.32

50 Day Range

MA: $6.70
Low: $5.07
High: $8.25

2 Week Range

Now: $5.30
Low: $3.85
High: $8.75

Volume

24,359 shs

Average Volume

311,532 shs

Market Capitalization

$418.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21